HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bensinger, W. I. Articles by Buckner, C. D. Search for Related Content PubMed PubMed Citation Articles by Bensinger, W. I. Articles by Buckner, C. D.

Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor

The Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; the Department of Medicine of the University of Washington, Seattle, Washington, USA

Key Words. Allogeneic • Transplantation • Peripheral blood stem cells

Dr. William I. Bensinger, Fred Hutchinson Cancer Research Center, 1124 Columbia Street, Seattle, WA 98104-2092, USA.

Recombinant G-CSF has been given to over 150 normal donors for the collection of allogeneic or syngeneic peripheral blood stem cells (PBSC). G-CSF was found to be well-tolerated with mild-moderate bone pain, edema and mild thrombocytopenia being the observed side effects. To date, approximately 90 unmodified primary PBSC transplants from HLA-identical related donors have been performed with engraftment that is, in general, considerably more rapid than marrow. Acute graft-versus-host-disease (GVHD), grades II-IV occurred in 47% of patients and grades III-IV in 17%. Despite the infusion of one to two logs more T cells, these results are not remarkably different than would be expected with marrow transplantation. There have also been successful reports of using G-CSF mobilized allogeneic PBSC following second transplants for graft rejection or relapse. Allogeneic PBSC have been infused without reconditioning for correction of graft failure and unmodified or CD34 selected PBSC have also been given with marrow to augment the dose of hematopoietic cells. Further studies are needed to define the role of allogeneic PBSC for transplantation, refine PBSC mobilization and collection techniques and to evaluate the long-term effects of cytokines in normal donors.

This article has been cited by other articles:

				H. Ince, M. Petzsch, H. D. Kleine, H. Schmidt, T. Rehders, T. Korber, C. Schumichen, M. Freund, and C. A. Nienaber Preservation From Left Ventricular Remodeling by Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Use of Granulocyte-Colony-Stimulating Factor (FIRSTLINE-AMI) Circulation, November 15, 2005; 112(20): 3097 - 3106. [Abstract] [Full Text] [PDF]

				T. Crough, M. Nieda, and A. J. Nicol Granulocyte Colony-Stimulating Factor Modulates {alpha}-Galactosylceramide-Responsive Human V{alpha}24+V{beta}11+ NKT Cells J. Immunol., October 15, 2004; 173(8): 4960 - 4966. [Abstract] [Full Text] [PDF]

				J. S. Forrester, M. J. Price, and R. R. Makkar Stem Cell Repair of Infarcted Myocardium: An Overview for Clinicians Circulation, September 2, 2003; 108(9): 1139 - 1145. [Full Text] [PDF]

				S. S. Joshi, J. C. Lynch, S. Z. Pavletic, S. R. Tarantolo, S. J. Pirruccello, A. Kessinger, and M. R. Bishop Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics Blood, September 15, 2001; 98(6): 1963 - 1970. [Abstract] [Full Text] [PDF]

				J. Banchereau, B. Pulendran, R. Steinman, and K. Palucka Will the Making of Plasmacytoid Dendritic Cells In Vitro Help Unravel Their Mysteries? J. Exp. Med., December 18, 2000; 192(12): F39 - F44. [Full Text] [PDF]

				Y.-J. Liu and B. Blom Introduction: TH2-inducing DC2 for immunotherapy Blood, April 15, 2000; 95(8): 2482 - 2483. [Full Text] [PDF]

				M. Arpinati, C. L. Green, S. Heimfeld, J. E. Heuser, and C. Anasetti Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells Blood, April 15, 2000; 95(8): 2484 - 2490. [Abstract] [Full Text] [PDF]

				E. M. Sloand, S. Kim, J. P. Maciejewski, F. Van Rhee, A. Chaudhuri, J. Barrett, and N. S. Young Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo Blood, April 1, 2000; 95(7): 2269 - 2274. [Abstract] [Full Text] [PDF]

				M. Engelhardt, H. Bertz, M. Afting, C. F. Waller, and J. Finke High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ Immunoselection J. Clin. Oncol., July 1, 1999; 17(7): 2160 - 2160. [Abstract] [Full Text] [PDF]

				J. Ferrara, K. Cooke, L Pan, and W Krenger The immunopathophysiology of acute graft-versus-host-disease Stem Cells, September 1, 1996; 14(5): 473 - 489. [Abstract]